Related Experiment Videos
Activated protein C resistance in pediatric inflammatory bowel disease
1Division of Gastroenterology and Nutrition, Schneider Children's Medical Center of Israel, Petah Tikva, Israel.
Insights
Activated protein C (APC) resistance, a common cause of thrombosis, was investigated in inflammatory bowel disease (IBD) patients. The study found no significant role for APC resistance in the hypercoagulable state associated with IBD.
Area of Science:
- Gastroenterology
- Hematology
- Thrombosis Research
Background:
- Inflammatory bowel disease (IBD) is associated with a hypercoagulable state, with thrombosis observed in Crohn's disease patients.
- Activated protein C (APC) resistance is a leading inherited cause of venous thrombosis, accounting for a significant portion of idiopathic cases.
Purpose of the Study:
- To investigate the prevalence of APC resistance in patients with IBD.
- To determine if APC resistance contributes to the hypercoagulable state observed in IBD.
Main Methods:
- A screening method for APC resistance was employed.
- The study included 23 IBD patients (17 Crohn's disease, 6 ulcerative colitis) and 11 controls.
Main Results:
- One Crohn's disease patient showed a positive APC resistance screen; two others had borderline results.
- All control subjects exhibited normal APC resistance screening results.
- A patient with a history of thromboembolism had a normal APC resistance screen.
Conclusions:
- Activated protein C resistance does not appear to be a primary factor in the hypercoagulable state of IBD.
- Further research may be needed to fully elucidate the causes of thrombosis in IBD.
Background:
There is evidence for a hypercoagulable state in inflammatory bowel disease (IBD), and small vessel thrombosis has been identified in the bowel of patients with Crohn's disease, suggesting thrombosis as a possible etiologic factor. Activated protein C (APC) resistance is the most common inherited disorder leading to thrombosis and accounts for 30% to 40% of episodes of idiopathic venous thrombosis.
Methods:
The prevalence of APC resistance was studied in 23 patients with IBD (17 with Crohn's disease, 6 with ulcerative colitis) and in 11 control subjects with recurrent abdominal pain or celiac disease, using an APC resistance screening method.
Results:
One patient with Crohn's disease had a positive screen result, two patients (one with Crohn's, one with ulcerative colitis) had borderline results, and results in all of the control subjects were normal. One patient with Crohn's disease had a history of a thromboembolic event but had a normal screen result.
Conclusions:
Activated protein C resistance does not seem to play a major role in the etiology of the hypercoagulable state in inflammatory bowel disease.